GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » ROE %

US Neurosurgical Holding (US Neurosurgical Holding) ROE % : -96.13% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. US Neurosurgical Holding's annualized net income for the quarter that ended in Dec. 2023 was $-0.58 Mil. US Neurosurgical Holding's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $0.61 Mil. Therefore, US Neurosurgical Holding's annualized ROE % for the quarter that ended in Dec. 2023 was -96.13%.

The historical rank and industry rank for US Neurosurgical Holding's ROE % or its related term are showing as below:

USNU' s ROE % Range Over the Past 10 Years
Min: -95.14   Med: 10.1   Max: 33.36
Current: -95.14

During the past 13 years, US Neurosurgical Holding's highest ROE % was 33.36%. The lowest was -95.14%. And the median was 10.10%.

USNU's ROE % is ranked worse than
90.36% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.06 vs USNU: -95.14

US Neurosurgical Holding ROE % Historical Data

The historical data trend for US Neurosurgical Holding's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding ROE % Chart

US Neurosurgical Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 15.59 -28.14 -70.09 -86.62

US Neurosurgical Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 204.66 -36.46 -189.83 -80.13 -96.13

Competitive Comparison of US Neurosurgical Holding's ROE %

For the Medical Care Facilities subindustry, US Neurosurgical Holding's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Neurosurgical Holding's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US Neurosurgical Holding's ROE % distribution charts can be found below:

* The bar in red indicates where US Neurosurgical Holding's ROE % falls into.



US Neurosurgical Holding ROE % Calculation

US Neurosurgical Holding's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-0.816/( (1.239+0.645)/ 2 )
=-0.816/0.942
=-86.62 %

US Neurosurgical Holding's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-0.584/( (0.57+0.645)/ 2 )
=-0.584/0.6075
=-96.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


US Neurosurgical Holding  (OTCPK:USNU) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.584/0.6075
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.584 / 0)*(0 / 1.096)*(1.096 / 0.6075)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.8041
=ROA %*Equity Multiplier
=N/A %*1.8041
=-96.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-0.584/0.6075
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.584 / -0.112) * (-0.112 / -0.972) * (-0.972 / 0) * (0 / 1.096) * (1.096 / 0.6075)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 5.2143 * 0.1152 * N/A % * 0 * 1.8041
=-96.13 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


US Neurosurgical Holding ROE % Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850
US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.
Executives
Lawrence William St director 23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler director 43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii director
Alan Gold director, 10 percent owner, officer: President & Chairman 2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman 10 percent owner C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc 10 percent owner 711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines